血友病治疗市场按治疗层级、治疗模式、最终用户和分销管道划分－2025-2032 年全球预测

预计到 2032 年，血友病治疗市场规模将成长至 254.8 亿美元，复合年增长率为 6.64%。

主要市场统计数据
基准年2024年	152.3亿美元
预计2025年	162.6亿美元
预测年份：2032年	254.8亿美元
复合年增长率（%）	6.64%

对当前血友病治疗动态、临床进展、患者期望以及相关人员决策的策略重点有清晰且令人信服的定位

在科学突破、治疗方式转变以及支付者和政策制定者日益增长的关注的推动下，血友病治疗领域正在迅速演变。近期的治疗方法创新正在重塑围绕持续获益和改善生活品质的临床讨论，促使相关人员重新评估临床路径和长期照护模式。同时，患者的期望也在改变。患者和看护者都越来越寻求能够降低出血频率、简化给药并最大程度减少生活方式干扰的治疗方法。这些期望正在影响临床医生、卫生系统和製造商的投资和服务设计重点。

同时，监管机构正在调整新治疗方法的审批路径，并制定循证策略和核准后监测计画。支付方也同样加强了对比较有效性和总医疗成本的审查，鼓励製造商将其上市策略与价值证明和基于结果的合约相结合。同时，诊断技术和数位医疗解决方案的进步也增强了监测能力，并带来了更主动的管理。总而言之，这些动态为寻求实现永续患者为中心的医疗保健的开发商、医疗保健提供者和政策制定者带来了机会，也带来了复杂性。

科学突破、付款人演变和分散护理模式的融合如何重塑整个血友病生态系统的临床应用和策略重点

在科学创新、支付者行为和医疗服务现代化的共同作用下，血友病领域正在发生一场变革性转变。基因编辑和基因替代疗法正在推动人们从长期替代疗法转向更持久解决方案的潜在转变，从而重塑临床试验设计、长期追踪计画和生产策略。同时，替代疗法的改进，包括延长半衰期的製剂和替代给药方式，正在持续减轻治疗负担并扩大治疗选择。

付款人参与度正从交易报销逐渐成熟，转向关注治疗结果和总成本，这奖励製造商展示其在现实世界中的有效性和患者报告的治疗结果。同时，医疗服务交付也日益分散，家庭输液、远端监控和社区专科诊所如今能够适应复杂的治疗方案。从数位化依从性工具到远端因素层级监控，科技推动因素正在减少个人化医疗的障碍，同时产生新的证据类型。这些力量正在汇聚，创造一种新格局：策略敏捷性、强大的证据产生能力和以患者为中心的服务将决定哪些创新技术能够获得广泛的临床应用并保持商业性可行性。

不断变化的关税政策对采购、物流和合约结构的实际影响会影响血友病治疗的连续性和商业性稳定性。

2025年，关税框架和跨境贸易政策的调整，为筹资策略、供应链韧性以及各治疗类别的价格谈判带来了重要的考量。製造商和经销商正在重新评估其采购足迹和物流，以减少可能影响医疗保健系统和患者负担能力的潜在成本转嫁。为此，许多相关人员优先考虑供应链的可视性和合约的灵活性，以应对间歇性的成本波动和海关相关的延误。

采购团队越来越青睐多元化的供应商网路和近岸外包方案，以降低关税波动带来的风险。同时，合约策略正转向长期协议，其中包含明确的服务水准和紧急条款，以维持医疗服务的连续性。这些变化也促使製造商重新考虑地域发布顺序，并改善与付款人和医疗系统的价值沟通，因为这些系统在关税引发的成本压力方面最为显着。最终，关税变化的累积影响凸显了整合商业和营运规划的必要性，以便在保障患者用药管道的同时保持商业性永续性。

全面洞察治疗方式、治疗形式、治疗环境和通路的细分，揭示差异化的价值创造机会

以细分为重点的洞察揭示了临床需求、治疗环境和通路的交汇点，从而影响采用路径和服务设计。从治疗层级维度来看，基因疗法与替代疗法展现出不同的发展重点。基因为基础的疗法需要长期的安全监测、专业化生产和已证实的疗效，而替代疗法则注重给药的便捷性、供应链的可靠性和临床差异化。另一方面，按需疗法则强调快速取得、急性护理协调和紧急应变。

考虑最终使用者概况（家庭医疗保健、医院、专科诊所）可以揭示护理环境如何影响服务要求和商业性推广。家庭医疗保健模式需要分散分销、看护者教育和远端监控解决方案，而以医院为中心的照护则强调机构处方、住院物流和急性护理整合。专科诊所是复杂个案管理、多学科协作和註册主导证据收集的中心。最后，分析医院和零售药局的通路可以揭示采购路径和病患接触点的差异。医院药局通常负责机构承包和住院支持，而零售药局则影响门诊病人依从性、可及性和社区级病患教育。整合治疗层级、治疗模式、最终使用者和分销管道的观点，使相关人员能够确定与针对每个患者群体的价值提案一致的服务模式。

全球主要地区在监管、报销和医疗保健服务方面的差异如何导致差异化的获取动态和商业性方法

区域动态塑造监管预期、医疗服务提供规范和支付方框架，并直接影响临床应用和商业策略。在美洲，创新的采用通常伴随着支付方的严格审查和复杂的基于结果的合约试点。公共和私人支付方需要全面的证据和真实世界数据来证明高成本干预措施的合理性，而病患权益团体则影响可及性途径和政策重点。各州和领地之间的政策差异使得区域参与策略成为必要，这又增加了一层复杂性。

在欧洲、中东和非洲，多样化的监管结构和报销途径需要量身定制的市场策略。有些国家强调集中式卫生技术评估和价值论证，而有些国家则维持分散式采购机制，优先考虑成本控制和处方集管理。在资源匮乏的环境中，药物的可及性通常依赖分级定价模式以及与非政府组织的伙伴关係。在亚太地区，快速现代化的医疗保健体系和庞大的公共支付方既带来了机会，也带来了限制。虽然某些地区的监管灵活性可能会加快新疗法的核准，但报销时间表和预算影响评估仍然是药物采用的关键决定因素。综上所述，这些区域特征凸显了将临床证据产生、定价策略和相关人员参与与当地监管机构和支付方期望相协调的重要性。

成功企业在不断发展的血友病护理领域所特有的关键能力、伙伴关係模式和证据策略

公司层面的动态决定了哪些公司已取得临床进展并永续获得药物，哪些公司面临重重障碍。策略领导力、生产规模和强大的证据产生能力，使先进疗法的先驱和成熟的生技药品製造商能够应对复杂的监管环境，并确保报销谈判顺利进行。投资于分散式生产能力、低温运输物流和治疗中心专业培训计画的公司，可以显着减少启动摩擦，并支持持续治疗。

研发公司、专业药局、付款方和供应商网路之间的合作，促进了病患识别、治疗启动和纵向监测的整合路径。数位化依从性平台、远端医疗追踪和集中式註册等技术集成，透过产生真实世界的结果和提高患者保留率，扩展了价值提案。相反，在上市后证据和相关人员参与方面投入不足的公司，往往会面临付款方的抵制，临床应用进展缓慢。总而言之，最成功的公司展现出将科学差异化与卓越营运、牢固的相关人员以及以临床、经济和患者为中心的证据策略相结合的能力。

领导团队可采取的策略重点，以协调证据产生、供应弹性、付款人参与和以病人为中心的服务，从而产生持久影响

行业领导者应采取一系列优先行动，使临床创新与付款人期望、营运弹性和以患者为中心的设计保持一致。首先，将可靠的真实世界证据纳入开发计划，以预测付款人需求并支持基于结果的合约。将註册、远端监控和患者报告的结果纳入核准后计划，使公司能够展示持续的临床效益并阐明其价值提案。其次，投资于供应链灵活性和区域物流，以减轻与关税相关的中断，并确保患者能够不间断地获得药物。近岸外包、供应商多元化以及与经销商签订应急协议有助于保持连续性。

第三，制定个人化的上市方案，以反映当地监管和报销的细微差别。儘早与卫生技术评估机构合作，调整经济模型以反映实际治疗路径，并准备有针对性的临床和付款方材料。第四，加强病患支持基础设施，以促进居家照护、遵从性和心理社会支持。最后，促进付款方与医疗服务提供者之间的伙伴关係，探索创新的合约方式、风险分担安排和综合护理路径。这些综合行动可以加速先进治疗方法的负责任应用，同时保障病患的可及性并展现永续的价值。

透明的混合方法研究设计将专家的初步访谈与系统的二次分析相结合，提供了基于相关人员的可复製的见解

为了确保观点平衡、结论可靠，我们将结构化的一手资料研究与系统性的二次研究结合。一手资料包括与临床专家、付款人、供应链专业人员和患者权益代表的深入访谈，以了解实践现状、报销考虑和生活体验。这些对话推动了假设驱动型研究的发展，并指南了有针对性的后续研究，以检验新兴主题。二次性研究综述涵盖同侪审查文献、监管指南、临床试验报告和公共文件，以支持在当前科学和监管背景下的解读。

数据三角测量用于协调不同的输入，并突出相关人员之间的共同见解。该方法包括定性编码以识别重复出现的主题，以及基于情境的分析以探索针对政策和市场变化的合理营运回应。在适当的情况下，确定了调查方法的局限性和边界条件，包括需要持续累积证据的领域，例如新治疗方法的长期安全性和现实世界有效性。资料来源、受访者概况和分析假设的透明度支持可复製性，并允许使用者将研究结果应用于自己的策略框架。

简洁的综合强调了相关人员的协作、证据的完整性和操作的敏捷性是将创新转化为病患可及性的关键因素。

血友病治疗领域正处于曲折点，科学进步、支付方审查和商业需求交织在一起。持久的治疗创新有望减轻治疗负担并改善患者预后，但实现这一目标需要有针对性的实证策略、韧性十足的供应链以及细緻入微的市场参与。相关人员若能积极主动地将临床开发与支付方需求结合，投资于病患支援和监测基础设施，并根据当地情况自订分销策略，则最有可能将创新转化为可及的医疗保健。

持续的进步需要製造商、医疗保健提供者、付款人和患者群体通力合作，共同创造平衡临床效益与可负担性和公平可及性的途径。持续监测监管和政策变化、投资真实世界证据以及提高营运灵活性至关重要。面对复杂的情况，清晰的策略和跨部门合作将决定哪些治疗方法能为血友病患者带来有意义且可扩展的影响。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 基于 CRISPR 的基因治疗方法在A型血友病 A中的广泛应用提供了持续的因子表达，减少了终生输血的需要
• 艾美珠单抗等双特异性单株抗体治疗的扩展正在重塑存在抑制剂开发风险的A型血友病 A患者的预防通讯协定
• 穿戴式科技与数位依从性平台的整合度不断提高，可即时监测出血事件和液体依从性
• 与一次性基因疗法（如批量 cocogenic loxaparvovec）相关的监管和定价挑战正在影响市场进入和报销决策。
• 利用国际血友病登记处的真实世界数据来制定个人化预防方案和综合健康经济模型
• 开发半衰期延长的重组因子 VIII 和因子 IX 产品，延长给药间隔，以提高患者的便利性和生活质量
• 新兴的以患者为中心的结果测量和远端医疗服务，以优化血友病患者群体的远距照护管理和依从性支持

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：血友病治疗市场（依治疗层级）

• 基因治疗
• 替代疗法

9. 血友病治疗市场（依治疗模式）

• 一经请求
• 预防

第 10 章 血友病治疗市场（依最终用户划分）

• 家庭医疗保健
• 医院
• 专科诊所

第 11 章血友病治疗市场（依通路）

• 医院药房
• 零售药局

第十二章血友病治疗市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章血友病治疗市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 血友病治疗市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Roche Holding AG
  • Takeda Pharmaceutical Company Limited
  • Swedish Orphan Biovitrium AB
  • Bayer AG
  • CSL Limited
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Octapharma AG
  • Grifols, SA
  • BioMarin Pharmaceutical Inc.

The Hemophilia Treatment Market is projected to grow by USD 25.48 billion at a CAGR of 6.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 15.23 billion
Estimated Year [2025]	USD 16.26 billion
Forecast Year [2032]	USD 25.48 billion
CAGR (%)	6.64%

A clear and compelling orientation to current hemophilia care dynamics, clinical advances, patient expectations, and the strategic priorities shaping stakeholder decisions

The hemophilia treatment landscape is undergoing a rapid period of evolution driven by scientific breakthroughs, shifts in care delivery, and heightened attention from payers and policymakers. Recent therapeutic innovations have reframed clinical conversations around durable benefit and quality-of-life improvements, prompting stakeholders to reassess clinical pathways and long-term care models. At the same time, patient expectations are changing: individuals and caregivers increasingly seek treatments that reduce bleeding frequency, simplify administration, and minimize lifestyle disruption. These expectations are influencing how clinicians, health systems, and manufacturers prioritize investment and service design.

Concurrently, regulatory authorities have adjusted pathways to account for novel modalities, shaping evidence-generation strategies and post-approval monitoring plans. Payers have likewise intensified scrutiny on comparative effectiveness and total cost of care, which encourages manufacturers to align launch strategies with value demonstration and outcomes-based contracting. In parallel, advances in diagnostics and digital health solutions are enhancing monitoring capabilities and enabling more proactive management. Taken together, these dynamics create both opportunity and complexity for developers, providers, and policy-makers seeking to deliver sustainable, patient-centric care.

How converging scientific breakthroughs, payer evolution, and decentralized care models are reshaping clinical adoption and strategic priorities across the hemophilia ecosystem

Transformative shifts in the hemophilia space are emerging from confluence of scientific innovation, payer behavior, and care delivery modernization. Gene-editing and gene-replacement approaches are prompting long-range thinking about a potential shift from chronic replacement regimens to more durable solutions, which in turn is reshaping clinical trial design, long-term follow-up plans, and manufacturing strategies. At the same time, improvements in replacement therapies, including extended half-life products and alternative delivery formats, continue to lower treatment burden and expand therapeutic choice.

Payer engagement has matured from transactional reimbursement to an emphasis on outcomes and total cost of care, creating incentives for manufacturers to prove real-world effectiveness and patient-reported outcomes. Meanwhile, care delivery is decentralizing as home-based infusion, remote monitoring, and specialized community clinics become more capable of supporting complex regimens. Technological enablers-from digital adherence tools to remote factor-level monitoring-are reducing barriers to individualized care while generating new types of evidence. Together, these forces are creating a landscape in which strategic agility, robust evidence generation, and patient-centered services determine which innovations achieve widespread clinical adoption and sustained commercial viability.

Practical implications of evolving tariff policies on procurement, logistics, and contractual structures that affect access continuity and commercial stability in hemophilia treatments

In 2025, adjustments to tariff frameworks and cross-border trade policies have created material considerations for procurement strategies, supply chain resilience, and pricing negotiations across therapeutic categories. Manufactures and distributors are reassessing sourcing footprints and logistics to mitigate potential cost pass-throughs that can affect affordability for both health systems and patients. In response, many stakeholders are prioritizing supply chain visibility and contractual flexibility to manage intermittent cost fluctuations and customs-related delays.

Procurement teams are increasingly favoring diversified supplier networks and nearshoring options to reduce exposure to tariff volatility. Concurrently, contracting strategies are shifting toward longer-term agreements with defined service levels and contingency clauses to preserve continuity of care. These changes are also prompting manufacturers to reconsider geographic launch sequencing and to refine value communication to payers and health systems where tariff-induced cost pressures are most pronounced. Ultimately, the cumulative impact of tariff changes emphasizes the need for integrated commercial and operational planning to protect patient access while maintaining commercial sustainability.

Comprehensive segmentation insights connecting therapeutic modalities, treatment modes, care settings, and distribution pathways to reveal differentiated value creation opportunities

Segment-focused insights reveal where clinical needs, care settings, and delivery channels intersect to influence adoption pathways and service design. When studying the therapeutic class dimension, the contrast between gene therapy and replacement therapy clarifies divergent development priorities: gene-based approaches require long-term safety surveillance, specialized manufacturing, and outcomes demonstration, whereas replacement therapies concentrate on dosing convenience, supply chain reliability, and incremental clinical differentiation. From the treatment mode perspective, the distinction between on-demand treatments and prophylaxis illuminates differing patient engagement models and resource utilization; prophylactic regimens center on preventing bleeding episodes and supporting continuous adherence programs, while on-demand approaches emphasize rapid access, acute care coordination, and emergency readiness.

Consideration of end user profiles-home healthcare, hospitals, and specialized clinics-shows how care setting influences service requirements and commercial outreach. Home healthcare models demand decentralized distribution, caregiver education, and remote monitoring solutions, whereas hospital-centric care leans on institutional formularies, inpatient logistics, and acute care integration. Specialized clinics act as hubs for complex case management, multidisciplinary coordination, and registry-driven evidence collection. Finally, distribution channel analysis across hospital pharmacy and retail pharmacy underscores different procurement pathways and patient touchpoints; hospital pharmacies often handle institutional contracting and inpatient support, while retail pharmacies influence outpatient adherence, accessibility, and community-level patient education. By integrating therapeutic class, treatment mode, end user, and distribution channel perspectives, stakeholders can identify tailored value propositions and aligned service models for distinct patient cohorts.

How regional regulatory, reimbursement, and care delivery variations across major global regions translate into differentiated access dynamics and commercial approaches

Regional dynamics shape regulatory expectations, care delivery norms, and payer frameworks in ways that directly affect clinical adoption and commercial strategy. In the Americas, innovation adoption is often accompanied by intense payer scrutiny and sophisticated outcomes-based contracting pilots; public and private payers demand comprehensive evidence packages and real-world data to justify higher-cost interventions, while patient advocacy groups influence access pathways and policy priorities. Policy variation across states and provinces adds another layer of complexity that requires localized engagement strategies.

Across Europe, Middle East & Africa, diverse regulatory architectures and reimbursement pathways necessitate bespoke market approaches. Some countries emphasize centralized health technology assessment and value demonstration, while others maintain decentralized procurement mechanisms that prioritize cost containment and formulary management. Access in lower-resource settings often hinges on tiered pricing models and partnerships with non-governmental organizations. In the Asia-Pacific region, a mix of rapidly modernizing healthcare systems and large public payers creates both opportunity and constraint. Regulatory agility in certain jurisdictions can accelerate approvals for novel therapies, but reimbursement timelines and budget impact assessments remain critical determinants of uptake. Collectively, these regional characteristics underline the importance of aligning clinical evidence generation, pricing strategy, and stakeholder engagement with local regulatory and payer expectations.

Critical organizational capabilities, partnership models, and evidence strategies that distinguish successful companies in the evolving hemophilia treatment landscape

Company-level dynamics distinguish organizations that achieve clinical traction and sustainable access from those that face roadblocks. Strategic leadership, manufacturing scale, and robust evidence-generation capabilities enable advanced therapy pioneers and established biologics manufacturers to navigate complex regulatory landscapes and secure reimbursement dialogues. Firms that invest in distributed manufacturing capacity, cold-chain logistics, and specialized training programs for treating centers can materially reduce launch friction and support continuity of care.

Partnership models are also critical: collaborations between developers, specialty pharmacies, payers, and provider networks facilitate integrated pathways for patient identification, initiation of therapy, and long-term monitoring. Technology integration-such as digital adherence platforms, telehealth-enabled follow-up, and centralized registries-amplifies the value proposition by producing real-world outcomes and improving patient retention. Conversely, companies that under-invest in post-market evidence and stakeholder engagement often encounter payer pushback and slower clinical adoption. In sum, the most successful organizations demonstrate an ability to combine scientific differentiation with operational excellence, strong stakeholder relationships, and an evidence strategy that speaks to clinical, economic, and patient-centered endpoints.

Actionable strategic priorities for leadership teams to align evidence generation, supply resilience, payer engagement, and patient-centered services for sustained impact

Industry leaders should pursue a set of prioritized actions that align clinical innovation with payer expectations, operational resilience, and patient-centered design. First, embed robust real-world evidence generation into development plans to anticipate payer needs and support outcomes-based contracting. By integrating registries, remote monitoring, and patient-reported outcomes into post-approval programs, organizations can demonstrate sustained clinical benefits and inform value propositions. Second, invest in supply chain flexibility and regional logistics to mitigate tariff-related disruptions and ensure uninterrupted patient access; nearshoring, diversified suppliers, and contingency agreements with distributors can preserve continuity.

Third, develop bespoke launch playbooks that reflect local regulatory and reimbursement nuances: engage early with health technology assessment bodies, tailor economic models to reflect real-world care pathways, and prepare targeted materials for clinical and payer audiences. Fourth, strengthen patient support infrastructures that facilitate home-based care, adherence, and psychosocial support; comprehensive patient services increase persistence and optimize clinical outcomes. Finally, cultivate payer and provider partnerships that explore innovative contracting approaches, risk-sharing arrangements, and integrated care pathways. These combined actions will accelerate responsible adoption of advanced therapies while protecting patient access and demonstrating sustainable value.

A transparent, mixed-methods research design combining expert primary interviews and systematic secondary analysis to deliver reproducible, stakeholder-informed insights

The research approach combined structured primary engagement with systematic secondary synthesis to ensure balanced perspectives and credible conclusions. Primary inputs included in-depth interviews with clinical experts, payers, supply chain professionals, and patient advocacy representatives to capture operational realities, reimbursement considerations, and lived experience. These conversations informed the development of hypothesis-driven inquiry and guided targeted follow-up to validate emerging themes. Secondary review encompassed peer-reviewed literature, regulatory guidance, clinical trial reports, and public policy documents to anchor interpretations in current scientific and regulatory contexts.

Data triangulation was used to reconcile disparate inputs and to highlight convergent insights across stakeholders. The methodology included qualitative coding to identify recurrent themes and scenario-based analysis to explore plausible operational responses to policy and market shifts. Where appropriate, methodological limitations and boundary conditions were identified, including areas requiring ongoing evidence accumulation such as long-term safety and real-world effectiveness for novel modalities. Transparency about data sources, interview respondent profiles, and analytic assumptions supports reproducibility and helps users apply the findings within their own strategic frameworks.

A concise synthesis emphasizing cross-stakeholder collaboration, evidence alignment, and operational agility as the decisive factors for translating innovation into patient access

The hemophilia treatment environment is at an inflection point where scientific progress, payer scrutiny, and operational imperatives converge. Durable therapeutic innovations create the promise of reduced treatment burden and improved patient outcomes, yet realizing that promise depends on intentional evidence strategies, resilient supply chains, and finely tuned market engagement. Stakeholders that proactively align clinical development with payer requirements, invest in patient support and monitoring infrastructures, and adapt distribution strategies to regional realities will be best positioned to convert innovation into accessible care.

Sustained progress will require collaboration across manufacturers, providers, payers, and patient communities to co-create pathways that balance clinical benefit with affordability and equitable access. Continued monitoring of regulatory and policy shifts, investment in real-world evidence, and agility in operational execution are essential. In the face of complexity, strategic clarity and cross-functional coordination will determine which therapies achieve meaningful, scalable impact for people living with hemophilia.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Increasing adoption of CRISPR-based gene therapy approaches in hemophilia A to achieve durable factor expression and reduce lifelong infusion requirements
• 5.2. Expansion of bispecific monoclonal antibody treatments such as emicizumab reshaping prophylaxis protocols for hemophilia A patients with inhibitor development risk
• 5.3. Growing integration of digital treatment adherence platforms and wearable technology to monitor bleeding episodes and infusion compliance in real time
• 5.4. Regulatory and pricing challenges associated with one-time gene therapies like valoctocogene roxaparvovec influencing market access and reimbursement decisions
• 5.5. Utilization of real-world data from international hemophilia registries to inform personalized prophylactic regimens and comprehensive health economic modeling
• 5.6. Development of extended half-life recombinant factor VIII and IX products extending dosing intervals to improve patient convenience and quality of life
• 5.7. Emergence of patient-centric outcome measures and telemedicine services optimizing remote care management and adherence support for hemophilia populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hemophilia Treatment Market, by Therapeutic Class

• 8.1. Gene Therapy
• 8.2. Replacement Therapy

9. Hemophilia Treatment Market, by Treatment Mode

• 9.1. On-Demand
• 9.2. Prophylaxis

10. Hemophilia Treatment Market, by End User

• 10.1. Home Healthcare
• 10.2. Hospitals
• 10.3. Specialized Clinics

11. Hemophilia Treatment Market, by Distribution Channel

• 11.1. Hospital Pharmacy
• 11.2. Retail Pharmacy

12. Hemophilia Treatment Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Hemophilia Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Hemophilia Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Roche Holding AG
  • 15.3.2. Takeda Pharmaceutical Company Limited
  • 15.3.3. Swedish Orphan Biovitrium AB
  • 15.3.4. Bayer AG
  • 15.3.5. CSL Limited
  • 15.3.6. Novo Nordisk A/S
  • 15.3.7. Pfizer Inc.
  • 15.3.8. Octapharma AG
  • 15.3.9. Grifols, S.A.
  • 15.3.10. BioMarin Pharmaceutical Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. HEMOPHILIA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 70. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 71. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 72. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 73. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 74. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 75. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 76. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 77. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 78. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 79. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 82. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 83. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 84. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 85. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 86. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 87. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 88. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 89. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 92. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 93. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 94. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 95. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 96. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 97. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 98. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 109. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 112. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 113. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 114. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 115. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 116. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 117. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 118. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 119. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 122. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 123. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 124. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 125. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 126. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 127. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 128. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 129. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 132. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 133. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 134. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 135. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 136. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 137. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 138. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 139. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 142. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 143. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 144. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 145. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 146. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 147. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 148. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 154. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 155. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 156. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 157. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 158. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 159. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 160. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 161. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 164. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 165. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 166. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 167. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 168. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 169. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 170. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 171. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 174. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 175. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 176. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 177. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 178. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 179. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 180. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 181. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 184. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 185. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 186. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 187. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 188. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 189. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 190. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 191. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 194. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 195. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 196. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 197. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 198. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 199. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 200. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 201. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 204. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 205. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 206. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 207. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 208. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 209. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 210. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 214. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 215. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 216. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 217. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 218. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 219. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 220. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 221. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 222. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 223. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 224. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 225. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 228. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 229. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 230. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 231. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 232. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 233. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 236. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 237. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 238. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 239. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 240. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 241. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 242. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 243. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 244. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 245. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 246. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 247. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 248. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 249. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 252. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 253. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 254. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 255. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 256. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 257. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 258. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 259. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 260. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 261. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 262. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 263. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 264. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 265. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 266. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 267. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 268. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 269. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 270. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 271. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 272. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 273. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 274. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 275. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 276. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 277. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 278. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 279. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 280. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 281. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 282. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 283. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 284. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 285. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 286. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 287. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 288. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 289. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 290. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 291. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 292. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 293. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 294. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 295. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 296. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 297. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 298. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 299. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 300. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 301. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 302. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 303. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 304. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 305. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 306. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 307. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 308. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 309. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 310. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 311. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 312. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 313. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 314. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 315. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 316. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 317. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 318. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 319. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 320. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 321. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 322. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 323. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 324. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 325. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 326. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 327. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
• TABLE 328. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
• TABLE 329. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 330. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 331. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 332. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 333. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 334. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024